First Author: G.Palexas UK
Co Author(s): O. Almossawi
Back to previous
Cholesterol and HDL have previously been implicated in the disease process associated with Age-related Macular Degeneration (AMD).
Retrospective cohort study. Patients undergoing anti-VEGF therapy for non AMD conditions Diabetic Maculopathy (DMO), Central retinal vein occlusions (CRVO) and Branch vein occlusions (BRVO) were compared to patients with neo-vascular Age-related Macular Degeneration (nAMD).
Routinely collected data between September 2015 and December 2016 were analysed using descriptive statistics. Chi square tests for associations were used for categorical data. Logistic regression was used for binary outcomes. Linear regression was used for continuous outcomes. P values <0.05 were considered statistically significant. Comparisons of Cholesterol and HDL in the DMO, CRVO, BRVO and nAMD groups were made.
Data from 379 patients with mean age 71 years were obtained. 196 (51.6%) had DMO, 117 (30.8%) had nAMD, 33 (8.9%) had CRVO, and 33 (8.9%) had BRVO. There were no differences in HDL and cholesterol between the patients with CRVO and BRVO. Those with nAMD tended to have the higher mean cholesterol than non-nAMD (4.56 ± 1.13 vs 4.27 ±1.12) and higher mean HDL (1.45 ± 0.43 vs1.28 ± 0.38), neither of which reached statistical significance after adjusting for age, gender and diabetes. The adjusted odds ratios of having high versus low cholesterol (≥ 5.0 mmol/L) and high versus low HDL (≥1.5 mmol/L) for the nAMD group of patients versus non-nAMD are 1.9 (95% CI 0.9 to 3.9, p=0.09) and 1.4 (95% CI 0.7 to 2.8, p=0.31) respectively.
There is a trend towards patients with neo-vascular AMD of having higher cholesterol and HDL, however in this small sample size the differences failed to reach statistical significance.